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Background
Although depression, anxiety and cognitive impairment
are commonly seen in HIV-positive patients, to date most
studies have not focused on aging subjects. We examined
frequency and determinants of depression, anxiety and
cognitive impairment in patients aged >50 years.
Methods
Cross-sectional study of 169 HAART-treated HIV-infected
patients aged  >50 years. Patients were administered the
IPAT Anxiety Scale Questionnaire (ASQ), the IPAT
Depression Scale Questionnaire (CDQ), and a battery of
17 standardized neuropsychological tests (NPT) as part of
psychiatric, medical, and laboratory assessment.
Summary of results
Patient characteristics: age 56.8 years (mean, range 50–
85), male gender 82.8%, CD4 count 555/cmm (mean, SD
+347), subjects with HIV-RNA <50 cp/mL 70.7%, patients
with previous AIDS events 43.8%, current HAART
schemes: EFV-based 32.5%, PI-based 63.3%, and NVP-
based 4.1% patients. Overall, scores consistent with anxi-
ety (ASQ score>6) and depression (CDQ score>5) were
observed in 66.9% and in 54.4% of patients. Cognitive
impairment (<1 SD from the normative mean on >2 age
and gender adjusted NPT, or <2 SD from the mean on >1
adjusted NPT) was present in 46.8% patients. Cognitive
performance was not influenced by anxiety and depres-
sion scores. Similarly, age, sex, risk factors, CDC stage,
plasma HIV-RNA, duration of HAART exposure were not
related to anxiety and depression scores. Patients aged >60
years had greater impairment at NPT than patients aged
50–60 years (mean NPT-Z4 score: -2.0 vs. -0.7; p = 0.002).
Moreover, patients with ASQ scores consistent with anxi-
ety had CD4 counts lower than patients reporting no anx-
iety (mean CD4 count/cmm 447 vs. 598; p = 0.026).
Finally, EFV-treated patients were more likely to show
summary scores consistent with absence of both depres-
sion (CDQ<5: 41.8% vs. 60.5%; p = 0.022) and anxiety
(ASQ<6: 54.5% vs. 72.8%; p = 0.018) than PI-treated sub-
jects.
Conclusion
Anxiety and depression were reported in nearly two-thirds
of patients aged >50 years. Anxiety was associated with
low CD4 cell count. Cognitive impairment was present in
almost 50% of patients aged >50 years. Cognitive decline
increased with increasing age. By contrast, anxiety and
depression did not influence cognitive performance. Anx-
iety and depression were less common in EFV-treated
patients, suggesting a prescription bias. Physicians must
be aware of the high prevalence of psychiatric and cogni-
tive disturbances in HIV patients aged >50 years.
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